Navigation MenuRealWire Limited

Delivering Relevance, Releasing Influence

Tweet Facebook LinkedIn
Press Release

PAREXEL ClinPhone® RTSM Named Leader Of Interactive Response Technology In New Benchmark Report From Industry Standard Research

Media
Links

London, UK, 15 December 2014 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that its randomisation and trial supply management (RTSM) services, ClinPhone® RTSM, ranked as the leader of Interactive Response Technology (IRT), according to a new global survey of pharmaceutical and biotechnology companies by Industry Standard Research (ISR). ClinPhone RTSM was also cited as the most preferred and widely used IRT solution.

PAREXEL Informatics’ ClinPhone RTSM service has been used in more than 3,200 studies involving more than 270,000 sites and 2.2 million patients since 1993. Additionally, ClinPhone RTSM has been used in more than 250 studies using covariate adaptive randomisation techniques and 160 studies using adaptive trial designs. ClinPhone RTSM is a key component of the Perceptive MyTrials® eClinical platform, an integrated suite of applications for managing clinical trials. PAREXEL continues to strengthen its leadership position in RTSM. Through the recent acquisition and integration of ClinIntel, PAREXEL’s next generation ClinPhone RTSM service offers clients an effective visual design approach that streamlines the system delivery process. Both ClinPhone RTSM and Perceptive MyTrials are available through the Perceptive® Partner Program.

“ISR’s report provides further endorsement of ClinPhone RTSM as the preferred provider and leader of IRT solutions worldwide,” said Xavier Flinois, President of PAREXEL Informatics. “Randomisation and trial supply management activities are critical to the success of our clients’ clinical development journeys. Our ClinPhone RTSM services are agile, flexible and scalable allowing us to address the complexity of different development phases, study types, geographic regions and client timelines.”

In this report, 105 respondents rated 24 IRT vendors (including in-house systems) across 20 different system attributes based on user experience. Forty-eight percent of respondents rated PAREXEL ClinPhone RTSM as the leader in the IRT field. More information about ISR’s 2014 IRT Market Dynamics and Service Provider Benchmarking Report can be found at www.ISRreports.com.

# # #

Press contacts:
onechocolate communications
Sue Grant and Charlotte Ward
Tel. +44 (0)20 7437 0227
Parexel@onechocolatecomms.co.uk

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organisation, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 81 locations in 51 countries around the world, and has approximately 15,980 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL, PAREXEL Informatics, Perceptive MyTrials and ClinPhone are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisition of ClinIntel Limited, or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 as filed with the SEC on November 3, 2014, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.